Trial Profile
A Phase Ib Investigation of Pembrolizumab in Combination With Intratumoral Injection of Clostridium Novyi-NT in Patients With Treatment-Refractory Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Jul 2023
Price :
$35
*
At a glance
- Drugs Clostridium novyi-NT (Primary) ; Pembrolizumab (Primary) ; Doxycycline
- Indications Chordoma; Head and neck cancer; Malignant melanoma; Nasopharyngeal cancer; Solid tumours; Squamous cell cancer; Vulval disorders
- Focus Adverse reactions
- 19 Apr 2023 Results(n=16) assessing safety and efficacy of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors presented at the 114th Annual Meeting of the American Association for Cancer Research
- 18 Apr 2022 Planned End Date changed from 1 Oct 2021 to 1 Oct 2024.
- 18 Apr 2022 Planned primary completion date changed from 1 Oct 2021 to 1 Oct 2024.